Monday 03 November 2025
Internal Reference Number: FOI_8832
Date Request Received: 07/08/2025 00:00:00
Date Request Replied To: 26/08/2025 00:00:00
This response was sent via: By Email
Request Summary: Data request
Request Category: Companies
| Question Number 1: The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q2’25(April, May, and June 2025) a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025) If possible, segment patients by brand used e.g 5 patients on Cuvitru b. How of these Ig treated PID patients are naïve (new starts) in Q2’25(April, May, and June 2025)? | |
| Answer To Question 1: Please see our response to all questions in the file attached. Apologies that we are unable to answer part b - how many Ig treated patients were naive/new starts. (as data is not recorded in this way) To accompany this answer to question 1 please also see the documents listed below:  13188 - FOI_8832 - Data Request - FOR ISSUE.xlsx | |
| Question Number 2: The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q2’25(April, May, and June 2025) a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used? b. How of these Ig treated SID patients are naïve (new starts) in Q2’25(April, May, and June 2025)? | |
| Answer To Question 2: Please see attached | |
| Question Number 3: The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q2’25(April, May, and June 2025) a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used? b. How of these Ig treated CIDP patients are naïve (new starts) in Q2’25(April, May, and June 2025)? | |
| Answer To Question 3: Please see attached | |
| Question Number 4: The number of immunoglobulin vials/volume in grams distributed to Salisbury NHS Foundation Trust in each month for April, May, and June 2025, broken down by product (see below). I would also like to request the number of patients Salisbury NHS Foundation Trust by brand if available • Vigam • Flebogamma DIF • Gammaplex • Gamunex-C • Octagam • Gamten • Kiovig • Intratect • Privigen • Iqymune • Gammanorm • Subcuvia • Subgam • Hizentra • Hyqvia • Cuvitru • Panzyga • Xembify • Cutaquig • Vyvgart (Efgartigimod | |
| Answer To Question 4: Please see attached | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
